Non-invasive drug delivery across the blood–brain barrier (BBB) represents a significant
advancement in treating neurological diseases. The BBB is a tightly packed layer of …

Neurodegenerative diseases (NDDs) significantly contribute to morbidity and mortality
worldwide. The suboptimal effect of currently used therapeutic approaches administered via …

The blood–brain barrier (BBB) limits the access of substances to the central nervous system
(CNS) which hinders the treatment of pathologies affecting the brain and the spinal cord …

Neurodegenerative diseases (NDDs) affect more than 50 million people worldwide, posing
a significant global health challenge as well as a high socioeconomic burden. With aging …

Ischemic stroke continues to be one of the leading causes of death and disability in the adult
population worldwide. The currently used pharmacological methods for the treatment of …

Alzheimer's disease (AD) is a progressive neurodegenerative disease that affects most
people worldwide. AD is a complex central nervous system disorder. Several drugs have …

Huntington's Disease (HD) is a severe neurodegenerative disorder lacking effective
diagnostic and treatment options. However, there is increasing interest in the potential of …

Current available animal and in vitro cell-based models for studying brain-related
pathologies and drug evaluation face several limitations since they are unable to reproduce …

This review article discusses the potential of nanomaterials in targeted therapy and
immunomodulation for stroke-induced immunosuppression. Although nanomaterials have …

Gliomas are typical malignant brain tumours affecting a wide population worldwide.
Operation, as the common treatment for gliomas, is always accompanied by postoperative …